Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (CAN)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02958111 |
Recruitment Status : Unknown
Verified June 2019 by Jun Ma, MD, Sun Yat-sen University.
Recruitment status was: Active, not recruiting
First Posted : November 8, 2016
Last Update Posted : June 12, 2019
|
Sponsor:
Sun Yat-sen University
Collaborators:
Tongji Hospital
Wuhan Union Hospital, China
Peking University
Air Force Military Medical University, China
Second Affiliated Hospital of Soochow University
West China Hospital
The First Affiliated Hospital of Guangdong Pharmaceutical University
First People's Hospital of Foshan
Fifth Affiliated Hospital, Sun Yat-Sen University
Cancer Hospital of Guizhou Province
Xiangya Hospital of Central South University
First Affiliated Hospital of Zhejiang University
Jilin Provincial Tumor Hospital
Henan Cancer Hospital
Hunan Cancer Hospital
The First Affiliated Hospital of Xiamen University
Cancer Hospital of Guangxi Medical University
Information provided by (Responsible Party):
Jun Ma, MD, Sun Yat-sen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | December 2021 |
Estimated Study Completion Date : | December 2023 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):